Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019: T-VEC shows improved survival over cytokine therapy in patients with melanoma

Igor Puzanov, MD, Director of the Early Phase Clinical Trials Program and Chief of Melanoma at Roswell Park Comprehensive Cancer Center, led research on the immunotherapy T-VEC, or talimogene laherparepvec, to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

Dr. Puzanov is senior author on the study, which is the first to report the ad hoc analysis of progression-free survival (PFS) for T-VEC compared to cytokine-based immunotherapy with granulocyte-macrophage colony-stimulating factor, or GM-CSF, in the pivotal OPTiM randomised phase III trial (NCT identifier no. 00769704).

T-VEC is an injectable immunotherapy designed to kill melanoma cells in the skin and lymph nodes.

An oncolytic virus, it targets cancer cells without affecting normal, nonmalignant cells.

Results show that single-agent T-VEC demonstrated an improvement in progression-free survival compared to GM-CSF in the overall intent-to-treat population, in whom 12-month survival was estimated to be 14.4% for T-VEC and 4.6% for GM-CSF.

The finding was driven primarily by patients with advanced, stage–4 melanoma, in whom 12-month progression-free survival was expected to be 19.9% for T-VEC and only 3.2% for GM-CSF.

“Our findings are consistent with previous data showing a more pronounced overall survival benefit with T-VEC for patients with local/regional melanoma, or disease that had not spread to other organs,” says Dr. Puzanov. “Significantly, we observed no difference in median progression-free survival between patients with progression and those whose disease had not progressed.”

A subgroup analysis shows that patients who did not progress within six months of therapy with T-VEC had 50% reduced chance of future progression compared to patients treated with GM-CSF.

Source: Roswell Park Comprehensive Cancer Center

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation